in Genitourinary, Gastrointestinal, and Breast Cancers, Plus Sarcoma and Melanoma at ASCO 2023: Drs Rini, Lewis, Trent, Luke, Kunz, and Lustberg
ZUMA-7 Primary OS Analysis Supports Use of Axi-cel As Second-line SOC in R/R LBCL
Sintilimab Plus Chemoradiotherapy Improves EFS in Locally Advanced Nasopharyngeal Carcinoma
Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer
%20copy.png?fit=crop&auto=format)
